ByInvesting.com • Sep 09, 2019 Novo Nordisk to cut insulin prices in the U.S. COPENHAGEN (Reuters) - Novo Nordisk (CSE:NOVOb) will offer cheaper insulin to U.S. diabetics, the Danish drugmaker ...
Novo Nordisk and United Laboratories International’s subsidiary, United Biotechnology Co. have entered into a potentially $2 ...
Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...
Novo Nordisk will pay $200 million up front, with up to $1.8 billion in additional payments down the line, The Wall Street ...
KEY TAKEAWAYS Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss ...
Beyond diabetes and obesity, Novo Nordisk is diversifying its portfolio ... recently received approval in the EU for treating haemophilia A or B with inhibitors. Alhemo is not approved in the ...
The United Laboratories International Holdings Limited and Novo Nordisk (NVO) announced earlier that Novo Nordisk and TUL’s wholly-owned ...
Building upon its already impressive obesity drug portfolio, Novo Nordisk A/S has licensed a triple agonist of the receptors ...
Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a ...
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
UBT251 has been approved for U.S. clinical trials for adult type 2 diabetes, overweight or obesity, and chronic kidney disease. The announcement came as Novo Nordisk announced it was expanding its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback